Iroko Pharmaceuticals' nonsteroidal anti-inflammatory drug Zorvolex, or diclofenac, was approved by the FDA for treatment of adults with mild to moderate acute pain. Zorvolex was cleared at a 20% lower dose strength than currently available treatments, reducing the risk of strokes, acute renal failures and other serious adverse events.
Iroko's acute pain drug Zorvolex wins FDA approval
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan